CPRIT Awards 32 Grants

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Projects support product development, prevention and research advancements across Texas

The Cancer Prevention and Research Institute of Texas awarded 20 grants through its product development program, five grants through its prevention program and seven recruitment grants through its research program, totaling more than $65 million.

With a total requested amount of approximately $33.9 million, these early translational research grants awarded to Texas institutions include projects developing therapeutics, devices and new drugs.

The awarded research grants total approximately $24 million. The awarded prevention grants, totaling approximately $7.3 million, support prevention services for underserved populations in Texas. The projects receiving grants focus on increasing HPV vaccination rates and providing access to colorectal and cervical cancer screening. The project receiving a competitive continuation grant provides screening, training and educational services related to colon cancer.

The awarded product development grants for early translational research are:

  • Baylor College of Medicinethree grants totaling $5,927,789: Novel Separase Inhibitors to Treat Refractory Breast Cancer, $2,000,000; Oral Stat3 Inhibitor as Targeted Treatment for Triple-negative Breast Cancer, $1,999,569; and NKT Cell Platform for Cancer Immunotherapy, $1,928,220.
  • MD Anderson Cancer Centerthree grants totaling $5,045,493: Genetic Engineering of T Cells as an “Off-the-shelf” Therapy for Leukemias and Lymphomas, $1,992,245; Blood-based Markers for Screening and Early Detection of Colorectal Neoplasia, $1,693,599; and High-throughput Flow-proteometric System in Screening Functional Complexes as Cancer Biomarkers, $1,359,649.
  • The University of Texas at Austinthree grants totaling $4,949,450: Preclinical Development of a Therapeutic Enzyme for Immune Checkpoint Inhibition in Cancer, $1,790,486; Image-guided Smart Laser Knife for Cancer Surgery, $1,694,460; and Pre-IND Development of OxaliTex, $1,464,504.
  • The University of Texas Southwestern Medical Centerthree grants totaling $4,521,535: New Antibody Therapy for Treating Leukemia, $2,000,000; Targeting the SWI/SNF Chromatin-remodeling Complex in Liver Cirrhosis and Hepatocellular Carcinoma, $1,357,880; and Targeting the DC-HIL Receptor for Anti-cancer Immunotherapy, $1,163,655.
  • The University of Texas Health Science Center at San Antoniotwo grants totaling $3,990,904: Druggable Targets that Regulate the Antitumor Activity of ER-beta, $1,998,444; and ESR1 Coregulator Binding Site Inhibitors (ECBIs) as Novel Therapeutics to Target Hormone Therapy Resistant Metastatic Breast Cancer, $1,992,460.
  • The University of Texas Health Science Center at Houstontwo grants totaling $3,481,666: Targeting an Elusive Foe: Development of K-ras Inhibitors, $1,969,826; and Development of a Novel K-ras Therapeutic, $1,511,840.
  • Texas A&M University System Health Science CenterTherapeutic Targeting of Skp2/Ck1 to Restore Nuclear p27, $1,999,979.
  • The University of Texas Medical Branch at Galveston Inhibitors of Hydrogen Sulfide Biosynthesis: Preclinical Development of Novel Colorectal Cancer Therapies, $1,605,119.
  • Methodist Hospital Research InstituteImmunotherapy Targeting Triple Negative Breast Cancer Using NY-ESO-1-Specific TCRs and Blockade of Immune, $1,592,992.
  • University of North Texas Health Science Center at Fort WorthSelective Tumor Delivery of Anti-cancer Agents in Ovarian Cancer Therapy, $742,048.

The awarded prevention grants include funding for evidence-based cancer prevention services:

  • Texas Tech University Health Sciences Center: ACCION for Rural West Texas, $1,467,820.
  • Texas Tech University Health Sciences Center: Get FIT to Stay Fit. Stepping Up to Fight Colorectal Cancer in the Panhandle, $1,455,409.
  • MD Anderson Cancer Center: Improving Cervical Cancer Screening and Prevention in the Lower Rio Grande Valley Through Public Outreach, Patient Navigation and Telementoring, $1,441,085.
  • The University of Texas Medical Branch at Galveston: A Multi-pronged Approach to Increase HPV Vaccination Rates among Adolescents 9-17 years of Age from Galveston and Brazoria Counties, $1,406,919
  • And a competitive continuation/expansion grant for Texas A&M University System Health Science Center: Continuation and Expansion of Texas A&M’s Colon Cancer Screening, Training, Education and Prevention Program, $1,500,000.

Recruitment grants awarded indicate only approval to negotiate offers; at this time the candidates have not accepted offers. The research grants for recruitment were awarded to:

  • Robert Mattrey, for recruitment to The University of Texas Southwestern Medical Center from the University of California, San Diego, $6,000,000.
  • Samara Reck-Peterson, for recruitment to The University of Texas Southwestern Medical Center Department of Cell Biology from Harvard Medical School, $4,000,000.
  • Andres Leschziner, for recruitment to The University of Texas Southwestern Medical Center from Harvard University, $4,000,000.
  • Issam El Naqa, for recruitment to The University of Texas Southwestern Medical Center from McGill University Health Center, $4,000,000.
  • Xi Chen, for recruitment to Baylor College of Medicine from Weill Cornell Medical College, $2,000,000.
  • Marcin Imielinski, for recruitment to MD Anderson Cancer Center from Broad Institute of Harvard, $2,000,000.
  • Melanie Samuel, for recruitment to Baylor College of Medicine from Harvard University, $2,000,000.

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login